EP3727423
MEÐFERÐ VIÐ EFNASKIPTASJÚKDÓMUM MEÐ AFBRIGÐUM AF FGF21
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
21.12.2018EP published:
22.5.2024EP application number:
18842846.0
EP translation filed:
8.7.2024Grant published:
15.9.2024EPO information:
European Patent Register
Max expiry date:
20.12.2038Expiry date:
20.12.2026Next due date:
31.12.2026
Title in English:
TREATMENT OF METABOLIC DISORDERS WITH FGF21 VARIANTSLanguage of the patent:
English
Timeline
Today
21.12.2018EP application
22.5.2024EP Publication
8.7.2024Translation submitted
15.9.2024Registration published
20.12.2026Expires
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056 Basel, CH
Inventor
Name:
GOLDFINE, AllisonAddress:
Cambridge, Massachusetts 02139, US
Name:
YI, Byungdoo AlexanderAddress:
Cambridge, Massachusetts 02139, US
Agent
Name:
G.H. Sigurgeirsson ehf.Address:
Borgartúni 26, 105, Reykjavík,
Priority
Number:
201762609489 PDate:
22.12.2017Country:
US
Classification
Categories:
A61K 38/18, A61K 45/06, A61P 3/06, A61P 3/04, A61P 9/10, A61P 5/50, A61P 9/12
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 10.12.2024
Expires: 20.12.2025
Payer: G.H. Sigurgeirsson ehf.
Number: 8
Paid: 11.12.2025
Expires: 20.12.2026
Payer: G.H. Sigurgeirsson ehf.